Skip to content
Inciteful Med

The Blueprint of Albinism: Genes and Subtypes

Last updated:

Oculocutaneous Albinism (OCA) is caused by genetic mutations that disrupt melanin production, affecting skin, hair, and eye color. Genetic testing is essential to confirm the exact subtype, predict future pigment changes, and rule out related health syndromes.

Key Takeaways

  • • Oculocutaneous Albinism (OCA) occurs when mutations disrupt the genes responsible for producing melanin.
  • • There are at least eight non-syndromic types of OCA, with OCA1 and OCA2 being the most common forms globally.
  • • Because different genetic mutations can look identical physically, genetic testing is required for an accurate diagnosis.
  • • Genetic testing helps predict whether pigment will develop over time and can rule out complex conditions like Hermansky-Pudlak Syndrome.
  • • Inheriting a combination of mild and severe genetic variants can result in better vision and more pigment than classic albinism.

Understanding the genetics of Oculocutaneous Albinism (OCA) is like looking at a complex biological blueprint. While the outward signs of albinism—fair skin, light hair, and vision changes—may look similar from person to person, the underlying genetic cause can vary significantly.

The Melanin Factory

To understand OCA, it helps to think of melanin production as a factory assembly line [1]. Melanin is the pigment that gives color to our hair, skin, and eyes and protects us from the sun [2].

  1. The Engine (Tyrosinase): This enzyme, powered by the TYR gene, is the “master switch” that starts the production of melanin [3].
  2. The Environment (pH Regulation): For the engine to work, the “factory” (a structure called a melanosome) must have the right acidity (pH). Genes like OCA2 and SLC45A2 act as climate control, making sure the environment is perfect for the tyrosinase engine to run [1][4].
  3. The Finishing Line: Other genes, like TYRP1 and DCT, help stabilize the process and determine the final color of the pigment [5][6].

When any of these genes have a mutation, the assembly line breaks down, resulting in less melanin or no melanin at all [2][7].

The Major Subtypes of OCA

There are at least eight known non-syndromic types of OCA, each linked to a specific gene [7][8].

OCA1 (TYR Gene)

This is the most common type worldwide [9].

  • OCA1A: The most severe form, where there is a total lack of tyrosinase activity. Hair and skin are white from birth and do not darken [10][3].
  • OCA1B: Often called “yellow albinism.” The engine works a little bit, allowing some pigment to develop in the hair (turning yellow or blond) and eyes over time [11][12].

OCA2 (OCA2 Gene)

This is the most common form in Sub-Saharan Africa [9]. It is usually milder than OCA1A, with hair color ranging from sandy-blond to light brown [13][14].

OCA3 (TYRP1 Gene)

Often called Rufous Albinism, it is more common in African and southern African populations [15][16]. Individuals may have reddish-brown skin and ginger hair [15].

OCA4 (SLC45A2 Gene)

This type is relatively rare worldwide but is one of the most common forms in Japan [4][17]. It looks very similar to OCA2.

Newer & Rarer Types

  • OCA6 (SLC24A5): Affects the transport of calcium needed for pigment [18].
  • OCA7 (LRMDA): Can present with significant vision issues but relatively normal skin and hair color [19][20].
  • OCA8 (DCT): The newest identified type, involving a breakdown at the very end of the melanin assembly line [21].

Why Genetic Testing is Essential

In the past, doctors diagnosed OCA based only on a person’s appearance (their phenotype). However, we now know that different genetic mutations (the genotype) can look exactly the same [14][22].

Next-Generation Sequencing (NGS)

Modern testing like Next-Generation Sequencing (NGS) or Whole Exome Sequencing (WES) allows doctors to look at many albinism-related genes all at once [23][2]. This is crucial because:

  • Accuracy: It confirms the specific subtype, which helps predict how pigment might change with age [24].
  • Ease of Testing: The test is usually very simple, often requiring just a cheek swab or a small saliva sample, which is especially easy for newborns.
  • Ruling Out Syndromes: It can identify if the albinism is part of a more serious condition, like Hermansky-Pudlak Syndrome (HPS), which affects blood clotting [25][26].
  • Family Planning: It provides clear information for parents about the 25% chance of passing the condition to future children [24][27].

Mixed Genetic Variants (Compound Heterozygosity)

Sometimes, a person inherits two different mutations in the same gene (compound heterozygosity) [11]. A well-known example involves the R402Q and S192Y variants in the TYR gene.

  • These are “mild” or “hypomorphic” variants. They don’t break the engine completely; they just slow it down [28][11].
  • If a child inherits one severe mutation and one mild variant like R402Q, they may have much more pigment and better vision than expected for classical albinism [28][29]. These cases are often missed without deep genetic screening [30].

Frequently Asked Questions

What are the different types of oculocutaneous albinism?
There are at least eight known non-syndromic types of OCA. The most common are OCA1, caused by mutations in the TYR gene, and OCA2. Other types, such as OCA3 and OCA4, vary in frequency depending on a person's geographic and ethnic background.
Why is genetic testing important for albinism?
Genetic testing confirms the exact subtype of albinism, which helps predict if your child's hair or skin might darken over time. It is also critical for ruling out more serious syndromic conditions, like Hermansky-Pudlak Syndrome, which require specialized medical care.
Can hair and skin color change if you have albinism?
Yes, depending on the specific genetic subtype. While people with severe forms like OCA1A typically do not develop pigment, those with types like OCA1B or OCA2 may notice their hair and eyes gradually darkening as they get older.
What does compound heterozygosity mean on my genetic report?
Compound heterozygosity happens when a person inherits two different genetic mutations in the same gene. In albinism, inheriting one severe mutation and one mild mutation can result in more pigment and better vision than someone with classic albinism.

Questions for Your Doctor

  • • Which specific genes were analyzed in my genetic test, and did it include the common hypomorphic variants like R402Q?
  • • Can you explain the difference between my child's (or my) clinical phenotype and the genetic findings? Why might they not perfectly match?
  • • Does my genetic report indicate 'compound heterozygosity,' and what does that mean for the long-term development of pigment?
  • • Are there any signs of syndromic albinism (like HPS) that were not captured by the initial genetic panel or clinical exam?

Questions for You

  • • Has anyone else in my family, even distant relatives, always been 'fairer' than the rest or had light-colored hair that darkened over time?
  • • How much pigment (in hair or skin) do I (or my child) currently have, and have I noticed any changes in color since birth?
  • • What is my priority for genetic testing: is it for personal clarity, family planning, or to better understand the potential visual outcome?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Oculocutaneous albinism in a patient with an OCA2 variant: molecular and clinical insights.

    Neissi M, Al-Mozani SK, Al-Zaalan AR, et al.

    Asian biomedicine : research, reviews and news 2025; (19(3)):154-163 doi:10.2478/abm-2025-0019.

    PMID: 40735666
  2. 2

    Strabismus and nystagmus in oculocutaneous albinism: clinical perspectives, diagnosis, and role of neurotransmitters.

    Dobhal V, Kumar A, Garg I, et al.

    Neurogenetics 2025; (26(1)):50 doi:10.1007/s10048-025-00830-x.

    PMID: 40531243
  3. 3

    Generation and characterization of retinal pigment epithelium from patient iPSC line to model oculocutaneous albinism (OCA)1A disease.

    Subramani J, Patlolla N, Battu R, et al.

    Journal of biosciences 2024; (49()).

    PMID: 38287676
  4. 4

    Ablation of Proton/Glucose Exporter SLC45A2 Enhances Melanosomal Glycolysis to Inhibit Melanin Biosynthesis and Promote Melanoma Metastasis.

    Liu Y, Chi W, Tao L, et al.

    The Journal of investigative dermatology 2022; (142(10)):2744-2755.e9 doi:10.1016/j.jid.2022.04.008.

    PMID: 35469906
  5. 5

    Biophysical Compatibility of a Heterotrimeric Tyrosinase-TYRP1-TYRP2 Metalloenzyme Complex.

    Lavinda O, Manga P, Orlow SJ, Cardozo T

    Frontiers in pharmacology 2021; (12()):602206 doi:10.3389/fphar.2021.602206.

    PMID: 33995009
  6. 6

    The TYRP1-mediated protection of human tyrosinase activity does not involve stable interactions of tyrosinase domains.

    Dolinska MB, Wingfield PT, Young KL, Sergeev YV

    Pigment cell & melanoma research 2019; (32(6)):753-765 doi:10.1111/pcmr.12791.

    PMID: 31077632
  7. 7

    Clinical and Mutation Spectrum of Autosomal Recessive Non-Syndromic Oculocutaneous Albinism (nsOCA) in Pakistan: A Review.

    Ullah MI

    Genes 2022; (13(6)) doi:10.3390/genes13061072.

    PMID: 35741834
  8. 8

    Comprehensive analysis of spectral distribution of a large cohort of Chinese patients with non-syndromic oculocutaneous albinism facilitates genetic diagnosis.

    Zhong Z, Gu L, Zheng X, et al.

    Pigment cell & melanoma research 2019; (32(5)):672-686 doi:10.1111/pcmr.12790.

    PMID: 31077556
  9. 9

    [A case for the inclusion of oculocutaneous albinism as a skin-related Neglected Tropical Disease].

    Aquaron R, Lund P, Baker C

    Medecine tropicale et sante internationale 2023; (3(4)) doi:10.48327/mtsi.v3i4.2023.434.

    PMID: 38390024
  10. 10

    Retinal Pigment Epithelium-Targeting Gene Therapy Corrects Ocular Symptoms in Mouse and Rat Models of Oculocutaneous Albinism Type I.

    Song L, Ren C, Luo M, et al.

    MedComm 2025; (6(11)):e70433 doi:10.1002/mco2.70433.

    PMID: 41122448
  11. 11

    Evidence that the Ser192Tyr/Arg402Gln in cis Tyrosinase gene haplotype is a disease-causing allele in oculocutaneous albinism type 1B (OCA1B).

    Lin S, Sanchez-Bretaño A, Leslie JS, et al.

    NPJ genomic medicine 2022; (7(1)):2 doi:10.1038/s41525-021-00275-9.

    PMID: 35027574
  12. 12

    Mutation analysis of a Chinese family with oculocutaneous albinism.

    Wang X, Zhu Y, Shen N, et al.

    Oncotarget 2016; (7(51)):84981-84988 doi:10.18632/oncotarget.13109.

    PMID: 27829221
  13. 13

    Genetic analyses of oculocutaneous albinism types 1 and 2 with four novel mutations.

    Yang Q, Yi S, Li M, et al.

    BMC medical genetics 2019; (20(1)):106 doi:10.1186/s12881-019-0842-7.

    PMID: 31196117
  14. 14

    Genetic Variability in Slovenian Cohort of Patients with Oculocutaneous Albinism.

    Hovnik T, Debeljak M, Tekavčič Pompe M, et al.

    Acta chimica Slovenica 2021; (68(3)):683-692.

    PMID: 34897530
  15. 15

    TYPES OF ALBINISM IN THE BLACK SOUTHERN AFRICA POPULATION.

    Kromberg JG, Bothwell J, Kidson SH, et al.

    East African medical journal 2012; (89(1)):20-7.

    PMID: 26845807
  16. 16

    Albinism research in a Southern African setting: unique findings.

    Kromberg JGR, Kerr RA

    Journal of community genetics 2025; (16(2)):107-116 doi:10.1007/s12687-025-00786-3.

    PMID: 40138079
  17. 17

    Clinical evaluation and molecular screening of a large consecutive series of albino patients.

    Mauri L, Manfredini E, Del Longo A, et al.

    Journal of human genetics 2017; (62(2)):277-290 doi:10.1038/jhg.2016.123.

    PMID: 27734839
  18. 18

    Mitochondrial NCKX5 regulates melanosomal biogenesis and pigment production.

    Zhang Z, Gong J, Sviderskaya EV, et al.

    Journal of cell science 2019; (132(14)) doi:10.1242/jcs.232009.

    PMID: 31201282
  19. 19

    Clinical and mutational characteristics of oculocutaneous albinism type 7.

    Kruijt CC, de Wit GC, van Minderhout HM, et al.

    Scientific reports 2024; (14(1)):7572 doi:10.1038/s41598-024-57969-0.

    PMID: 38555393
  20. 20

    Identification of a RAB32-LRMDA-Commander membrane trafficking complex reveals the molecular mechanism of human oculocutaneous albinism type 7.

    Butkovič R, Healy MD, de Heus C, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.02.04.636395.

    PMID: 39975051
  21. 21

    Biallelic mutations in L-dopachrome tautomerase (DCT) cause infantile nystagmus and oculocutaneous albinism.

    Volk AE, Hedergott A, Preising M, et al.

    Human genetics 2021; (140(8)):1157-1168 doi:10.1007/s00439-021-02285-0.

    PMID: 33959807
  22. 22

    A pathogenic haplotype, common in Europeans, causes autosomal recessive albinism and uncovers missing heritability in OCA1.

    Grønskov K, Jespersgaard C, Bruun GH, et al.

    Scientific reports 2019; (9(1)):645 doi:10.1038/s41598-018-37272-5.

    PMID: 30679655
  23. 23

    Identification of Five Novel Variants in Chinese Oculocutaneous Albinism by Targeted Next-Generation Sequencing.

    Qiu B, Ma T, Peng C, et al.

    Genetic testing and molecular biomarkers 2018; (22(4)):252-258 doi:10.1089/gtmb.2017.0211.

    PMID: 29437493
  24. 24

    Genetic analysis and prenatal diagnosis of 20 Chinese families with oculocutaneous albinism.

    Xu C, Xiang Y, Li H, et al.

    Journal of clinical laboratory analysis 2021; (35(2)):e23647 doi:10.1002/jcla.23647.

    PMID: 33124154
  25. 25

    The ophthalmic presentation of Hermansky-Pudlak syndrome 6.

    Hull S, Arno G, Holder GE, et al.

    The British journal of ophthalmology 2016; (100(11)):1521-1524 doi:10.1136/bjophthalmol-2015-308067.

    PMID: 26823395
  26. 26

    Instability of BLOC-2 and BLOC-3 in Chinese patients with Hermansky-Pudlak syndrome.

    Wei A, Yuan Y, Qi Z, et al.

    Pigment cell & melanoma research 2019; (32(3)):373-380 doi:10.1111/pcmr.12748.

    PMID: 30387913
  27. 27

    Genetic analyses of Vietnamese patients with oculocutaneous albinism.

    Thuong MTH, Anh LTL, Nhung VP, et al.

    Journal of clinical laboratory analysis 2022; (36(9)):e24625 doi:10.1002/jcla.24625.

    PMID: 35870188
  28. 28

    Mild form of oculocutaneous albinism type 1: phenotypic analysis of compound heterozygous patients with the R402Q variant of the TYR gene.

    Monfermé S, Lasseaux E, Duncombe-Poulet C, et al.

    The British journal of ophthalmology 2019; (103(9)):1239-1247 doi:10.1136/bjophthalmol-2018-312729.

    PMID: 30472657
  29. 29

    After an initial Hermansky-Pudlak syndrome clinical diagnosis, molecular testing reveals variants for oculocutaneous albinism type 1B: A case report.

    Serrano-González J, Montes-Rodríguez I, Renta JY, et al.

    Molecular genetics & genomic medicine 2024; (12(7)):e2493 doi:10.1002/mgg3.2493.

    PMID: 38994739
  30. 30

    Evaluating the Cysteine-Rich and Catalytic Subdomains of Human Tyrosinase and OCA1-Related Mutants Using 1 μs Molecular Dynamics Simulation.

    Woods T, Sergeev YV

    International journal of molecular sciences 2023; (24(17)) doi:10.3390/ijms241713032.

    PMID: 37685839

This page explains the genetics and subtypes of Oculocutaneous Albinism for educational purposes. Always consult a genetic counselor or doctor to interpret specific genetic test results and determine the best care plan.

Stay up to date

Get notified when new research about Oculocutaneous albinism is published.

No spam. Unsubscribe anytime.